Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer

NCT04382898 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04382898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04382898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Terminated
Start date
December 19, 2019
Completion date
January 23, 2024
Enrollment
75 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer